Signaturefd LLC Sells 2,425 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Signaturefd LLC lessened its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 47.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,634 shares of the company’s stock after selling 2,425 shares during the period. Signaturefd LLC’s holdings in Hims & Hers Health were worth $53,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its stake in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the period. Belpointe Asset Management LLC grew its stake in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after acquiring an additional 1,205 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new position in Hims & Hers Health during the fourth quarter worth about $155,000. Avantax Advisory Services Inc. acquired a new stake in Hims & Hers Health in the 1st quarter worth about $156,000. Finally, Cornerstone Investment Partners LLC bought a new stake in Hims & Hers Health in the 1st quarter valued at about $161,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 0.8 %

Shares of HIMS stock opened at $14.61 on Thursday. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74. The stock’s fifty day simple moving average is $18.60 and its 200 day simple moving average is $16.75. The firm has a market capitalization of $3.14 billion, a P/E ratio of -1,461.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. During the same period in the previous year, the business posted ($0.03) earnings per share. The business’s quarterly revenue was up 51.8% compared to the same quarter last year. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Analyst Ratings Changes

HIMS has been the subject of a number of analyst reports. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. Truist Financial upped their target price on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, May 22nd. Citigroup cut shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Finally, Piper Sandler reissued a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and an average target price of $20.29.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 7,500 shares of the business’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $24.50, for a total value of $183,750.00. Following the sale, the insider now owns 185,326 shares of the company’s stock, valued at $4,540,487. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Andrew Dudum sold 45,755 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $22.97, for a total value of $1,050,992.35. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $769,540.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $24.50, for a total transaction of $183,750.00. Following the completion of the sale, the insider now directly owns 185,326 shares in the company, valued at $4,540,487. The disclosure for this sale can be found here. In the last ninety days, insiders sold 538,701 shares of company stock worth $10,431,151. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.